Overview

High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

To assess the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe compared to high-intensity rosuvastatin in high atherosclerotic cardiovascular disease risk patients with type 2 diabetes

Phase:

Phase 4

Details

Lead Sponsor:

Yuhan Corporation

Treatments:

Ezetimibe
Rosuvastatin Calcium